Treatment progress of Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2019.12.004
- VernacularTitle: 霍奇金淋巴瘤治疗进展
- Author:
Jiaqi QIN
1
;
Wei XU
Author Information
1. Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
- Publication Type:Review
- Keywords:
Lymphoma, Hodgkin;
Drug therapy, combination;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2019;28(12):716-718
- CountryChina
- Language:Chinese
-
Abstract:
Hodgkin lymphoma (HL) is a highly curable disease, and even in advanced-stage patients, more than 90% of them can achieve long-term survival. Due to its few adverse reactions and good curative effect, the ABVD regimen is currently used as the standard first-line chemotherapy for HL. In order to further improve the efficacy, the new first-line combination therapies and salvage therapeutic regimens for relapsed/refractory HL are continuously updated, such as anti-CD30 monoclonal antibody brentuximab vedotin combined with immune checkpoint inhibitors or chemotherapy, programmed death receptor 1 with chemotherapy or chimeric antigen receptor T-cells are gradually showing their advantages. This article summarizes the treatment progress of HL at the 61st American Society of Hematology Annual Meeting 2019.
